Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine

References

• Aghemo A, Colombo M. (2013). Hepatocellular carcinoma in chronic hepatitis C: From bench to bedside. Semin Immunopathol 35:111–120
   PubMed Web of Science ®Google Scholar
• Ahn T, Yun CH. (2010). Molecular mechanisms regulating the mitochondrial targeting of microsomal cytochrome P450 enzymes. Curr Drug Metab 11:830–838
   PubMed Web of Science ®Google Scholar
• Aitken AE, Morgan ET. (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687–1693
   PubMed Web of Science ®Google Scholar
• Alissa EM. (2014). Medicinal herbs and therapeutic drugs interactions. Ther Drug Monit 36:413–422
   PubMed Web of Science ®Google Scholar
• Anandatheerthavarada HK, Biswas G, Mullick J, et al. (1999). Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP-dependent phosphorylation at ser128. EMBO J 18:5494–5504
   PubMed Web of Science ®Google Scholar
• Anandatheerthavarada HK, Sepuri NB, Avadhani NG. (2009). Mitochondrial targeting of cytochrome P450 proteins containing NH2-terminal chimeric signals involves an unusual TOM20/TOM22 bypass mechanism. J Biol Chem 284:17352–17363
   PubMed Web of Science ®Google Scholar
• Anderson GD. (2005). Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet 44:989–1008
   PubMed Web of Science ®Google Scholar
• Antunes Nde J, Cavalli RC, Marques MP, et al. (2015). Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients. Br J Clin Pharmacol 79:605–616
   PubMed Web of Science ®Google Scholar
• Aristoff PA, Garcia GA, Kirchhoff PD, Showalter HD. (2010). Rifamycins − Obstacles and opportunities. Tuberculosis (Edinb) 90:94–118
   PubMed Web of Science ®Google Scholar
• Asselah T, Bieche I, Laurendeau I, et al. (2005). Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064–2075
   PubMed Web of Science ®Google Scholar
• Assenat E, Gerbal-Chaloin S, Larrey D, et al. (2004). Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40:951–960
   PubMed Web of Science ®Google Scholar
• Atkinson A, Singleton AB, Steward A, et al. (1999). CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. Pharmacogenetics 9:31–35
   PubMedGoogle Scholar
• Avadhani NG, Sangar MC, Bansal S, Bajpai P. (2011). Bimodal targeting of cytochrome P450s to endoplasmic reticulum and mitochondria: The concept of chimeric signals. FEBS J 278:4218–4229
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, Self TH. (2013). Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29:1–12
   PubMed Web of Science ®Google Scholar
• Bahari A, Mehrzad J, Mahmoudi M, et al. (2014). Cytochrome P450 isoforms are differently up-regulated in aflatoxin B1-exposed human lymphocytes and monocytes. Immunopharmacol Immunotoxicol 36:1–10
   PubMed Web of Science ®Google Scholar
• Ballard C, Gauthier S, Corbett A, et al. (2011). Alzheimer's disease. Lancet 377:1019–1031
   PubMed Web of Science ®Google Scholar
• Bateman R. (2015). Alzheimer's disease and other dementias: Advances in 2014. Lancet Neurol 14:4–6
   PubMed Web of Science ®Google Scholar
• Bavner A, Sanyal S, Gustafsson JA, Treuter E. (2005). Transcriptional corepression by SHP: Molecular mechanisms and physiological consequences. Trends Endocrinol Metab 16:478–488
   PubMed Web of Science ®Google Scholar
• Bebia Z, Buch SC, Wilson JW, et al. (2004). Bioequivalence revisited: Influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618–627
   PubMed Web of Science ®Google Scholar
• Beltrao P, Albanese V, Kenner LR, et al. (2012). Systematic functional prioritization of protein posttranslational modifications. Cell 150:413–425
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–293
   PubMed Web of Science ®Google Scholar
• Beyeler C, Daly AK, Armstrong M, et al. (1994). Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: Influence of drug therapy and disease activity. J Rheumatol 21:1034–1039
   PubMed Web of Science ®Google Scholar
• Bieche I, Asselah T, Laurendeau I, et al. (2005). Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 332:130–144
   PubMed Web of Science ®Google Scholar
• Blake MJ, Gaedigk A, Pearce RE, et al. (2007). Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81:510–516
   PubMed Web of Science ®Google Scholar
• Blennow K, Mattsson N, Scholl M, et al. (2015). Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36:297–309
   PubMed Web of Science ®Google Scholar
• Bloom GS. (2014). Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Ho HK, Zhou S, Leow KY. (2006). Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7:715–727
   PubMed Web of Science ®Google Scholar
• Bonder MJ, Kasela S, Kals M, et al. (2014). Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics 15:860
   PubMed Web of Science ®Google Scholar
• Branch RA, Adedoyin A, Frye RF, et al. (2000). In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 68:401–411
   PubMed Web of Science ®Google Scholar
• Brash AR. (2009). Mechanistic aspects of CYP74 allene oxide synthases and related cytochrome P450 enzymes. Phytochemistry 70:1522–1531
   PubMed Web of Science ®Google Scholar
• Brendel C, Schoonjans K, Botrugno OA, et al. (2002). The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol 16:2065–2076
   PubMed Web of Science ®Google Scholar
• Briciu C, Neag M, Muntean D, et al. (2014). A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther 39:535–540
   PubMed Web of Science ®Google Scholar
• Cairns W, Smith CA, McLaren AW, Wolf CR. (1996). Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 271:25269–25276
   PubMed Web of Science ®Google Scholar
• Carcillo JA, Parise RA, Adedoyin A, et al. (1996). CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 91:149–159
   PubMed Web of Science ®Google Scholar
• Carroll K, Gomez C, Shapiro L. (2004). Tubby proteins: The plot thickens. Nat Rev Mol Cell Biol 5:55–63
   PubMed Web of Science ®Google Scholar
• Carvalho TM, Cavalli Rde C, Cunha SP, et al. (2011). Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 67:55–61
   PubMed Web of Science ®Google Scholar
• Chen WD, Wang YD, Meng Z, et al. (2011). Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim Biophys Acta 1812:888–892
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhen Y, Miksys S, et al. (2013). Potential role of CYP2D6 in the central nervous system. Xenobiotica 43:973–984
   PubMed Web of Science ®Google Scholar
• Chiang JY. (2009). Hepatocyte nuclear factor 4α regulation of bile acid and drug metabolism. Expert Opin Drug Metab Toxicol 5:137–147
   PubMed Web of Science ®Google Scholar
• Chida M, Yokoi T, Kosaka Y, et al. (1999). Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 9:601–605
   PubMedGoogle Scholar
• Chinta SJ, Pai HV, Upadhya SC, et al. (2002). Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res Mol Brain Res 103:49–61
   PubMedGoogle Scholar
• Choi YH, Yu AM. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793–807
   PubMed Web of Science ®Google Scholar
• Choi YM, An S, Lee EM, et al. (2012). CYP1A1 is a target of miR-892a-mediated post-transcriptional repression. Int J Oncol 41:331–336
   PubMed Web of Science ®Google Scholar
• Cholerton S, Boustead C, Taber H, et al. (1996). CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 6:261–263
   PubMedGoogle Scholar
• Chouraki V, Seshadri S. (2014). Genetics of Alzheimer's disease. Adv Genet 87:245–294
   PubMed Web of Science ®Google Scholar
• Chow CW, Davis RJ. (2006). Proteins kinases: Chromatin-associated enzymes? Cell 127:887–890
   PubMed Web of Science ®Google Scholar
• Christen U, Holdener M, Hintermann E. (2010). Cytochrome P450 2D6 as a model antigen. Dig Dis 28:80–85
   PubMed Web of Science ®Google Scholar
• Colclough K, Bellanne-Chantelot C, Saint-Martin C, et al. (2013). Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1α and 4α in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat 34:669–685
   PubMed Web of Science ®Google Scholar
• Cooke BR, Bligh SW, Cybulski ZR, et al. (2012). Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes. Drug Metab Dispos 40:70–75
   PubMed Web of Science ®Google Scholar
• Corchero J, Granvil CP, Akiyama TE, et al. (2001). The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260–1267
   PubMed Web of Science ®Google Scholar
• Correia MA, Wang Y, Kim SM, Guan S. (2014). Hepatic cytochrome P450 ubiquitination: Conformational phosphodegrons for E2/E3 recognition? IUBMB Life 66:78–88
   PubMed Web of Science ®Google Scholar
• Corsini A, Bortolini M. (2013). Drug-induced liver injury: The role of drug metabolism and transport. J Clin Pharmacol 53:463–474
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Kottilil S. (2015). Beyond interferon: Rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis 6:4–14
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Greenblatt DJ. (2005). The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33–60
   PubMed Web of Science ®Google Scholar
• Crewe HK, Notley LM, Wunsch RM, et al. (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874
   PubMed Web of Science ®Google Scholar
• Cruchaga C, Karch CM, Jin SC, et al. (2014). Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505:550–554
   PubMed Web of Science ®Google Scholar
• Cummings CT, Deryckere D, Earp HS, Graham DK. (2013). Molecular pathways: MERTK signaling in cancer. Clin Cancer Res 19:5275–5280
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP. (2010). Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 139:58–72
   PubMed Web of Science ®Google Scholar
• Dallas S, Chattopadhyay S, Sensenhauser C, et al. (2013). Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes. Drug Metab Dispos 41:689–693
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Tay S, Senn TD, et al. (2008). Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochem Pharmacol 75:1677–1687
   PubMed Web of Science ®Google Scholar
• Dilger K, Hofmann U, Klotz U. (2000). Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 67:512–520
   PubMed Web of Science ®Google Scholar
• Dixit V, Hariparsad N, Li F, et al. (2007). Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853–1859
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell,JV. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: Focus on in vitro studies. Clin Pharmacokinet 42:153–178
   PubMed Web of Science ®Google Scholar
• Donovan JL, Chavin KD, Devane CL, et al. (2004a). Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 32:906–908
   PubMed Web of Science ®Google Scholar
• Donovan JL, DeVane CL, Chavin KD, et al. (2003). Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 31:519–522
   PubMed Web of Science ®Google Scholar
• Donovan JL, DeVane CL, Chavin KD, et al. (2004b). Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 32:1333–1336
   PubMed Web of Science ®Google Scholar
• Dorado P, Penas LEM, de la Rubia A, LLerena A. (2009). Relevance of CYP2D6 −1584C > G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics 10:1083–1089
   PubMed Web of Science ®Google Scholar
• Doroshyenko O, Rokitta D, Zadoyan G, et al. (2013). Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 41:987–993
   PubMed Web of Science ®Google Scholar
• Dostalek M, Akhlaghi F, Puzanovova M. (2012). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51:481–499
   PubMed Web of Science ®Google Scholar
• Dreisbach AW. (2009). The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 86:553–556
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. (2008). The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 4:1065–1074
   PubMed Web of Science ®Google Scholar
• Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. (2003). Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73:41–50
   PubMed Web of Science ®Google Scholar
• Drici MD, Clement N. (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575–585
   PubMed Web of Science ®Google Scholar
• Duggal P, Thio CL, Wojcik GL, et al. (2013). Genome-wide association study of spontaneous resolution of hepatitis C virus infection: Data from multiple cohorts. Ann Intern Med 158:235–245
   PubMed Web of Science ®Google Scholar
• Durand E, Petit O, Tremblay L, et al. (2015). Social behavioral changes in MPTP-treated monkey model of Parkinson's disease. Front Behav Neurosci 9:42
   PubMed Web of Science ®Google Scholar
• Durr D, Stieger B, Kullak-Ublick GA, et al. (2000). St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604
   PubMed Web of Science ®Google Scholar
• Ebner T, Eichelbaum M. (1993). The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. Br J Clin Pharmacol 35:426–430
   PubMed Web of Science ®Google Scholar
• Edwards RJ, Price RJ, Watts PS, et al. (2003). Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282–288
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. (1986). The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22:49–53
   PubMed Web of Science ®Google Scholar
• Fargo K, Bleiler L. (2014). Alzheimer's Association report. Alzheimers Dement 10:e47–e92
   PubMed Web of Science ®Google Scholar
• Faucette SR, Wang H, Hamilton GA, et al. (2004). Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32:348–358
   PubMed Web of Science ®Google Scholar
• Ferraguti G, Pascale E, Lucarelli M. (2015). Alcohol addiction: A molecular biology perspective. Curr Med Chem 22:670–684
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Distrutti E, Zampella A. (2012). Farnesoid X receptor: From medicinal chemistry to clinical applications. Future Med Chem 4:877–891
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Donini A, et al. (2007). Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 13:298–309
   PubMed Web of Science ®Google Scholar
• Frank D, Jaehde U, Fuhr U. (2007). Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321–333
   PubMed Web of Science ®Google Scholar
• Frye RF, Zgheib NK, Matzke GR, et al. (2006). Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80:235–245
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A, Kirchheiner J. (2007). Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81:270–283
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Gaedigk R, Leeder JS. (2005). CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein? Biochem Biophys Res Commun 336:1241–1250
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Ndjountche L, Divakaran K, et al. (2007). Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: Characterization of gene duplication events. Clin Pharmacol Ther 81:242–251
   PubMed Web of Science ®Google Scholar
• Gerhard DS. Wagner L, Feingold EA, et al. (2004). The status, quality, and expansion of the NIH full-length cDNA project: The Mammalian Gene Collection (MGC). Genome Res 14:2121–2127
   PubMed Web of Science ®Google Scholar
• Gibbs JP, Hyland R, Youdim K. (2006). Minimizing polymorphic metabolism in drug discovery: Evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab Dispos 34:1516–1522
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U, et al. (2004). CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 75:213–222
   PubMed Web of Science ®Google Scholar
• Gillam EM, Hayes MA. (2013). The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development. Curr Top Med Chem 13:2254–2280
   PubMed Web of Science ®Google Scholar
• Girardin F, Daali Y, Gex-Fabry M, et al. (2012). Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. J Viral Hepat 19:568–573
   PubMed Web of Science ®Google Scholar
• Gjoneska E, Pfenning AR, Mathys H, et al. (2015). Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 518:365–369
   PubMed Web of Science ®Google Scholar
• Glaeser H, Drescher S, Eichelbaum M, Fromm MF. (2005). Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 59:199–206
   PubMed Web of Science ®Google Scholar
• Golab-Janowska M, Honczarenko K, Gawronska-Szklarz B, Potemkowski A. (2007). CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia. Neurol Neurochir Pol 41:113–121
   PubMed Web of Science ®Google Scholar
• Gomez A, Ingelman-Sundberg M. (2009). Epigenetic and microRNA-dependent control of cytochrome P450 expression: A gap between DNA and protein. Pharmacogenomics 10:1067–1076
   PubMed Web of Science ®Google Scholar
• Gong X, Liu Y, Zhang X, et al. (2013). Systematic functional study of cytochrome P450 2D6 promoter polymorphisms in the Chinese Han population. PLoS One 8:e57764
   PubMedGoogle Scholar
• Gonzalez FJ, Matsunaga T, Nagata K, et al. (1987). Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 6:149–161
   PubMedGoogle Scholar
• Gorski JC, Hall SD, Becker P, et al. (2000). In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 67:32–43
   PubMed Web of Science ®Google Scholar
• Goryachkina K, Burbello A, Boldueva S, et al. (2008). Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 64:275–282
   PubMed Web of Science ®Google Scholar
• Gough AC, Smith CA, Howell SM, et al. (1993). Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 15:430–432
   PubMed Web of Science ®Google Scholar
• Graham DK, DeRyckere D, Davies KD, Earp HS. (2014). The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14:769–785
   PubMed Web of Science ®Google Scholar
• Graves LM, Duncan JS, Whittle MC, Johnson GL. (2013). The dynamic nature of the kinome. Biochem J 450:1–8
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428–440
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2005a). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525–539
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. (2005b). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415–426
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. (2008). Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52:755–763
   PubMed Web of Science ®Google Scholar
• Haas CE, Brazeau D, Cloen D, et al. (2005). Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol 61:583–593
   PubMed Web of Science ®Google Scholar
• Haass C, Mandelkow E. (2010). Fyn-tau-amyloid: A toxic triad. Cell 142:356–358
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Dahlqvist R. (2001). Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173
   PubMed Web of Science ®Google Scholar
• Hara H, Adachi T. (2002). Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. Mol Pharmacol 61:194–200
   PubMed Web of Science ®Google Scholar
• Hardy J, Bogdanovic N, Winblad B, et al. (2014). Pathways to Alzheimer's disease. J Intern Med 275:296–303
   PubMed Web of Science ®Google Scholar
• Harhangi BS, Oostra BA, Heutink P, et al. (2001). CYP2D6 polymorphism in Parkinson's disease: The Rotterdam Study. Mov Disord 16:290–293
   PubMed Web of Science ®Google Scholar
• Harvey RD, Morgan ET. (2014). Cancer, inflammation, and therapy: Effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther 96:449–457
   PubMed Web of Science ®Google Scholar
• Headland SE, Norling LV. (2015). The resolution of inflammation: Principles and challenges. Semin Immunol 27:149–160
   PubMed Web of Science ®Google Scholar
• Hellum BH, Hu Z, Nilsen OG. (2007). The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100:23–30
   PubMed Web of Science ®Google Scholar
• Henderson CJ, McLaughlin LA, Scheer N, et al. (2015). Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol 87:733–739
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. (2015a). Neuroinflammation in Alzheimer's disease. Lancet Neurol 14:388–405
   PubMed Web of Science ®Google Scholar
• Heneka MT, Golenbock DT, Latz E. (2015b). Innate immunity in Alzheimer's disease. Nat Immunol 16:229–236
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lecluyse EL, Ferguson SS. (2007). Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196–1224
   PubMed Web of Science ®Google Scholar
• Hichiya H, Kuramoto S, Yamamoto S, et al. (2004). Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: Comparison with the known marmoset CYP2D19. Biochem Pharmacol 68:165–175
   PubMed Web of Science ®Google Scholar
• Hill-Burns EM, Wissemann WT, Hamza TH, et al. (2014). Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genomics 15:118
   PubMed Web of Science ®Google Scholar
• Hintermann E, Holdener M, Bayer M, et al. (2011). Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun 37:242–253
   PubMed Web of Science ®Google Scholar
• Hiroi T, Imaoka S, Funae Y. (1998). Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838–843
   PubMed Web of Science ®Google Scholar
• Hiroi T, Kishimoto W, Chow T, et al. (2001). Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142:3901–3908
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. (2015). Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148:751–761 e758
   PubMed Web of Science ®Google Scholar
• Ho MT, Kelly EJ, Bodor M, et al. (2011). Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Ann Hepatol 10:327–332
   PubMed Web of Science ®Google Scholar
• Ho SL, Kung MH, Li LS, et al. (1999). Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians. Eur J Neurol 6:323–329
   PubMed Web of Science ®Google Scholar
• Hoeke MO, Heegsma J, Hoekstra M, et al. (2014). Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS One 9:e88011
   PubMedGoogle Scholar
• Hosking LK, Boyd PR, Xu CF, et al. (2002). Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity. Pharmacogenomics J 2:165–175
   PubMedGoogle Scholar
• Hu Z, Yang X, Ho PC, et al. (2005). Herb–drug interactions: A literature review. Drugs 65:1239–1282
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu X, Kuang X, Liao D. (2013). CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population. Tumour Biol 34:2189–2193
   PubMed Web of Science ®Google Scholar
• Huang Y, Mucke L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222
   PubMed Web of Science ®Google Scholar
• Humphries C, Kohli MA, Whitehead P, et al. (2015). Alzheimer disease (AD) specific transcription, DNA methylation and splicing in twenty AD associated loci. Mol Cell Neurosci 67:37–45
   PubMed Web of Science ®Google Scholar
• Hwang-Verslues WW, Sladek FM. (2010). HNF4α – Role in drug metabolism and potential drug target? Curr Opin Pharmacol 10:698–705
   PubMed Web of Science ®Google Scholar
• Ikemura K, Iwamoto T, Okuda M. (2014). MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: Implication for intestinal barrier function. Pharmacol Ther 143:217–224
   PubMed Web of Science ®Google Scholar
• Ikenaga Y, Fukuda T, Fukuda K, et al. (2005). The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the −1584C to G substitution. Drug Metab Pharmacokinet 20:113–116
   PubMedGoogle Scholar
• Imran M, Manzoor S, Khattak NM, et al. (2014). Current and future therapies for hepatitis C virus infection: From viral proteins to host targets. Arch Virol 159:831–846
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Zhong XB, Hankinson O, et al. (2013). Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 41:1725–1731
   PubMed Web of Science ®Google Scholar
• Inui N, Akamatsu T, Uchida S, et al. (2013). Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. Clin Pharmacol Ther 94:702–708
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Suzuki S, Otsu K, et al. (2007). cAMP-mediated regulation of CYP enzymes and its application in chemotherapy. Drug Metab Lett 1:176–178
   PubMedGoogle Scholar
• Ittner LM, Gotz J. (2011). Amyloid-β and tau − A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12:65–72
   PubMed Web of Science ®Google Scholar
• Iyanagi T, Xia C, Kim JJ. (2012). NADPH-cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family. Arch Biochem Biophys 528:72–89
   PubMed Web of Science ®Google Scholar
• Jensen ON. (2004). Modification-specific proteomics: Characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 8:33–41
   PubMed Web of Science ®Google Scholar
• Jeong SW, Jang JY, Chung RT. (2012). Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol 18:347–356
   PubMedGoogle Scholar
• Ji Y, Schaid DJ, Desta Z, et al. (2014). Citalopram and escitalopram plasma drug and metabolite concentrations: Genome-wide associations. Br J Clin Pharmacol 78:373–383
   PubMed Web of Science ®Google Scholar
• Jiang G, Chakraborty A, Wang Z, et al. (2013). New aQTL SNPs for the CYP2D6 identified by a novel mediation analysis of genome-wide SNP arrays, gene expression arrays, and CYP2D6 activity. Biomed Res Int 2013:493019
   PubMedGoogle Scholar
• Jo Corbin C, Mapes SM, Lee YM, Conley AJ. (2003). Structural and functional differences among purified recombinant mammalian aromatases: Glycosylation, N-terminal sequence and kinetic analysis of human, bovine and the porcine placental and gonadal isozymes. Mol Cell Endocrinol 206:147–157
   PubMed Web of Science ®Google Scholar
• Joanne C, Paintaud G, Bresson-Hadni S, et al. (1994). Is debrisoquine hydroxylation modified during acute viral hepatitis? Fundam Clin Pharmacol 8:76–79
   PubMed Web of Science ®Google Scholar
• Johansson I, Oscarson M, Yue QY, et al. (1994). Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452–459
   PubMed Web of Science ®Google Scholar
• Johnson TN, Tucker GT, Rostami-Hodjegan A. (2008). Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 83:670–671
   PubMed Web of Science ®Google Scholar
• Joost O, Taylor CA, Thomas CA, et al. (1999). Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease. Mov Disord 14:590–595
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gomez-Lechon MJ, Castell JV. (2001). Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting. Hepatology 33:668–675
   PubMed Web of Science ®Google Scholar
• Jover R, Moya M, Gomez-Lechon MJ. (2009). Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4α. Curr Drug Metab 10:508–519
   PubMed Web of Science ®Google Scholar
• Kacevska M, Ivanov M, Ingelman-Sundberg M. (2012). Epigenetic-dependent regulation of drug transport and metabolism: An update. Pharmacogenomics 13:1373–1385
   PubMed Web of Science ®Google Scholar
• Kaczynski JA, Conley AA, Fernandez Zapico M, et al. (2002). Functional analysis of basic transcription element (BTE)-binding protein (BTEB) 3 and BTEB4, a novel Sp1-like protein, reveals a subfamily of transcriptional repressors for the BTE site of the cytochrome P4501A1 gene promoter. Biochem J 366:873–882
   PubMed Web of Science ®Google Scholar
• Kalaany NY, Mangelsdorf DJ. (2006). LXRS and FXR: The yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159–191
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet 386:896–912
   PubMed Web of Science ®Google Scholar
• Kamiyama Y, Matsubara T, Yoshinari K, et al. (2007). Role of human hepatocyte nuclear factor 4α in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 22:287–298
   PubMed Web of Science ®Google Scholar
• Kandalepas PC, Vassar R. (2012). Identification and biology of β-secretase. J Neurochem 120:55–61
   PubMed Web of Science ®Google Scholar
• Karch CM, Cruchaga C, Goate AM. (2014). Alzheimer's disease genetics: From the bench to the clinic. Neuron 83:11–26
   PubMed Web of Science ®Google Scholar
• Kawaguchi-Suzuki M, Frye RF, Zhu HJ, et al. (2014). The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos 42:1611–1616
   PubMed Web of Science ®Google Scholar
• Kawai J, Shinagawa A, Shibata K, et al. (2001). Functional annotation of a full-length mouse cDNA collection. Nature 409:685–690
   PubMed Web of Science ®Google Scholar
• Kawakami H, Ohtsuki S, Kamiie J, et al. (2011). Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 100:341–352
   PubMed Web of Science ®Google Scholar
• Kawashima H, Strobel HW. (1995). cDNA cloning of three new forms of rat brain cytochrome P450 belonging to the CYP4F subfamily. Biochem Biophys Res Commun 217:1137–1144
   PubMed Web of Science ®Google Scholar
• Kelly SL, Kelly DE. (2013). Microbial cytochromes P450: Biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us? Philos Trans R Soc Lond B Biol Sci 368:20120476
   PubMed Web of Science ®Google Scholar
• Kerkar N, Choudhuri K, Ma Y, et al. (2003). Cytochrome P4502D6(193-212): A new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170:1481–1489
   PubMed Web of Science ®Google Scholar
• Kevorkian JP, Michel C, Hofmann U, et al. (1996). Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 59:583–592
   PubMed Web of Science ®Google Scholar
• Khlifi R, Chakroun A, Hamza-Chaffai A, Rebai A. (2014). Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients. Mol Biol Rep 41:2591–2600
   PubMed Web of Science ®Google Scholar
• Kim DH, Yeo SH, Park JM, et al. (2014a). Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene 545:185–193
   PubMed Web of Science ®Google Scholar
• Kim IW, Han N, Burckart GJ, Oh JM. (2014b). Epigenetic changes in gene expression for drug-metabolizing enzymes and transporters. Pharmacotherapy 34:140–150
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kang HS, Jung SY, et al. (2010). Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med (Berl) 88:1123–1131
   PubMed Web of Science ®Google Scholar
• Kimura S, Umeno M, Skoda RC, et al. (1989). The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889–904
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. (2011). Complex drug interactions of HIV protease inhibitors 2: In vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 39:2329–2337
   PubMed Web of Science ®Google Scholar
• Kishimoto W, Hiroi T, Shiraishi M, et al. (2004). Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 145:699–705
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Lu H, Cui JY. (2011). Epigenetic regulation of drug processing genes. Toxicol Mech Methods 21:312–324
   PubMed Web of Science ®Google Scholar
• Klein C, Westenberger A. (2012). Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2:a008888
   PubMed Web of Science ®Google Scholar
• Knight JD, Pawson T, Gingras AC. (2013). Profiling the kinome: Current capabilities and future challenges. J Proteomics 81:43–55
   PubMed Web of Science ®Google Scholar
• Koh KH, Pan X, Shen HW, et al. (2014a). Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. J Biol Chem 289:3105–3113
   PubMed Web of Science ®Google Scholar
• Koh KH, Pan X, Zhang W, et al. (2014b). Kruppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6-humanized mice. Mol Pharmacol 86:727–735
   PubMed Web of Science ®Google Scholar
• Komoroski BJ, Zhang S, Cai H, et al. (2004). Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512–518
   PubMed Web of Science ®Google Scholar
• Komurasaki R, Imaoka S, Tada N, et al. (2010). LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6. Drug Metab Pharmacokinet 25:84–92
   PubMed Web of Science ®Google Scholar
• Krovat BC, Tracy JH, Omiecinski CJ. (2000). Fingerprinting of cytochrome P450 and microsomal epoxide hydrolase gene expression in human blood cells. Toxicol Sci 55:352–360
   PubMed Web of Science ®Google Scholar
• Kuncewicz T, Sheta EA, Goldknopf IL, Kone BC. (2003). Proteomic analysis of S-nitrosylated proteins in mesangial cells. Mol Cell Proteomics 2:156–163
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Kornbluth S. (2009). Caspases and kinases in a death grip. Cell 138:838–854
   PubMed Web of Science ®Google Scholar
• Kurokohchi K, Yoneyama H, Matsuo Y, et al. (1992). Effects of interleukin 1α on the activities and gene expressions of the cytochrome P4502D subfamily. Biochem Pharmacol 44:1669–1674
   PubMed Web of Science ®Google Scholar
• Labbe L, Sirois C, Pilote S, et al. (2000). Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425–438
   PubMedGoogle Scholar
• Lamb DC, Waterman MR. (2013). Unusual properties of the cytochrome P450 superfamily. Philos Trans R Soc Lond B Biol Sci 368:20120434
   PubMed Web of Science ®Google Scholar
• Lammers LA, Achterbergh R, de Vries EM, et al. (2015). Short-term fasting alters cytochrome p450-mediated drug metabolism in humans. Drug Metab Dispos 43:819–828
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cai MX, Thomas PE, et al. (2003). Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144:3382–3398
   PubMed Web of Science ®Google Scholar
• Lee FY, Lee H, Hubbert ML, et al. (2006). FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31:572–580
   PubMed Web of Science ®Google Scholar
• Lee JI, Zhang L, Men AY, et al. (2010). CYP-mediated therapeutic protein-drug interactions: Clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49:295–310
   PubMed Web of Science ®Google Scholar
• Lee SS, Cha EY, Jung HJ, et al. (2008a). Genetic polymorphism of hepatocyte nuclear factor-4α influences human cytochrome P450 2D6 activity. Hepatology 48:635–645
   PubMed Web of Science ®Google Scholar
• Lee SS, Cha EY, Jung HJ, et al. (2008b). Genetic polymorphism of hepatocyte nuclear factor-4α influences human cytochrome P450 2D6 activity. Hepatology 48:635–645
   PubMed Web of Science ®Google Scholar
• Lemke G. (2013). Biology of the TAM receptors. Cold Spring Harb Perspect Biol 5:a009076
   PubMed Web of Science ®Google Scholar
• Lemke G, Rothlin CV. (2008). Immunobiology of the TAM receptors. Nat Rev Immunol 8:327–336
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134
   PubMed Web of Science ®Google Scholar
• Lempiainen H, Muller A, Brasa S, et al. (2011). Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One 6:e18216
   PubMed Web of Science ®Google Scholar
• Leung TM, Nieto N. (2013). CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 58:395–398
   PubMed Web of Science ®Google Scholar
• Lewis DF. (2004). 57 varieties: The human cytochromes P450. Pharmacogenomics 5:305–318
   PubMed Web of Science ®Google Scholar
• Li H, Feng L, Xu Y, et al. (2006). The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women. Acta Oncol 45:597–601
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. (2006). Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4α and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34:756–764
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. (2014). Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66:948–983
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. (2001). Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535–567
   PubMed Web of Science ®Google Scholar
• Liu G, Bao X, Jiang Y, et al. (2014). Identifying the association between Alzheimer's disease and Parkinson's disease using genome-wide association studies and protein-protein interaction network. Mol Neurobiol 52:1629–1636
   PubMed Web of Science ®Google Scholar
• Llerena A, Cobaleda J, Martinez C, Benitez J. (1996). Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21:129–138
   PubMed Web of Science ®Google Scholar
• Llerena A, Dorado P, Ramirez R, et al. (2013). CYP2D6 -1584C > G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers. Pharmacogenomics 14:1973–1977
   PubMed Web of Science ®Google Scholar
• Lo HS, Chen CH, Hogan EL, et al. (1998). Genetic polymorphism and Parkinson's disease in Taiwan: Study of debrisoquine 4-hydroxylase (CYP2D6). J Neurol Sci 158:38–42
   PubMed Web of Science ®Google Scholar
• Locuson CW, Wienkers LC, Jones JP, Tracy TS. (2007). CYP2C9 protein interactions with cytochrome b5: Effects on the coupling of catalysis. Drug Metab Dispos 35:1174–1181
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128
   PubMed Web of Science ®Google Scholar
• Lu Y, Mo C, Zeng Z, et al. (2013). CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: Evidence from meta-analysis. PLoS One 8:e84413
   PubMed Web of Science ®Google Scholar
• Lu Y, Peng Q, Zeng Z, et al. (2014a). CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis. J Neurol Sci 336:161–168
   PubMed Web of Science ®Google Scholar
• Lu Y, Qin X, Li S, et al. (2014b). Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: A meta-analysis. J Neurol Sci 343:15–22
   PubMed Web of Science ®Google Scholar
• Lubbe S, Morris HR. (2014). Recent advances in Parkinson's disease genetics. J Neurol 261:259–266
   PubMed Web of Science ®Google Scholar
• Ma X, Chen J, Tian Y. (2015). Pregnane X receptor as the “sensor and effector” in regulating epigenome. J Cell Physiol 230:752–757
   PubMed Web of Science ®Google Scholar
• Ma Y, Bogdanos DP, Hussain MJ, et al. (2006). Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130:868–882
   PubMed Web of Science ®Google Scholar
• Madacsy L, Barkai L, Santa A, Krikovszky D. (2004). Altered distribution of the debrisoquine oxidative phenotypes in children with type 1 diabetes mellitus. Horm Res 61:176–179
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–431
   PubMed Web of Science ®Google Scholar
• Maeda N, Kasukawa T, Oyama R, et al. (2006). Transcript annotation in FANTOM3: Mouse gene catalog based on physical cDNAs. PLoS Genet 2:e62
   PubMedGoogle Scholar
• Mahrour N, Redwine WB, Florens L, et al. (2008). Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J Biol Chem 283:8005–8013
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, DeVane CL, et al. (2003). Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290:1500–1504
   PubMed Web of Science ®Google Scholar
• Marques MP, Coelho EB, Dos Santos NA, et al. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607–614
   PubMed Web of Science ®Google Scholar
• Martel-Laferriere V, Dieterich DT. (2014). Treating HCV in HIV 2013: On the cusp of change. Liver Int 34(Suppl 1):53–59
   Web of Science ®Google Scholar
• Martin H, Sarsat JP, de Waziers I, et al. (2003). Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 20:557–568
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R. (2006). Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4α requires coactivators peroxisomal proliferator activated receptor-γ coactivator 1α and steroid receptor coactivator 1. Mol Pharmacol 70:1681–1692
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Persson I, Bertilsson L, et al. (1996). A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42:713–719
   PubMed Web of Science ®Google Scholar
• Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. (2009). Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 3:169–190
   PubMedGoogle Scholar
• Matoulkova P, Pavek P, Maly J, Vlcek J. (2014). Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol 10:425–435
   PubMed Web of Science ®Google Scholar
• Matsunaga E, Zanger UM, Hardwick JP, et al. (1989). The CYP2D gene subfamily: Analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349–7355
   PubMed Web of Science ®Google Scholar
• Matzke GR, Frye RF, Early JJ, et al. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182–190
   PubMed Web of Science ®Google Scholar
• Maurer HH, Kraemer T, Springer D, Staack RF. (2004). Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: A synopsis. Ther Drug Monit 26:127–131
   PubMed Web of Science ®Google Scholar
• McConnachie LA, Phillips B, Bajpai M, et al. (2003). Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes. Drug Metab Dispos 31:1103–1107
   PubMed Web of Science ®Google Scholar
• McCune JS, Lindley C, Decker JL, et al. (2001). Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723–731
   PubMed Web of Science ®Google Scholar
• McDonald TJ, Ellard S. (2013). Maturity onset diabetes of the young: Identification and diagnosis. Ann Clin Biochem 50:403–415
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, et al. (2015). Type I interferons in infectious disease. Nat Rev Immunol 15:87–103
   PubMed Web of Science ®Google Scholar
• Meijerman I, Sanderson LM, Smits PH, et al. (2007). Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev 39:45–60
   PubMed Web of Science ®Google Scholar
• Mendel DB, Crabtree GR. (1991). HNF-1, a member of a novel class of dimerizing homeodomain proteins. J Biol Chem 266:677–680
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu K. (2014). Pharmacokinetic interactions between herbal medicines and prescribed drugs: Focus on drug metabolic enzymes and transporters. Curr Drug Metab 15:791–807
   PubMed Web of Science ®Google Scholar
• Meunier B, de Visser SP, Shaik S. (2004). Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. Chem Rev 104:3947–3980
   PubMed Web of Science ®Google Scholar
• Meyer MR, Peters FT, Maurer HH. (2009). The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic MDEA and its single enantiomers. Drug Metab Dispos 37:1152–1156
   PubMed Web of Science ®Google Scholar
• Miksys S, Rao Y, Hoffmann E, et al. (2002). Regional and cellular expression of CYP2D6 in human brain: Higher levels in alcoholics. J Neurochem 82:1376–1387
   PubMed Web of Science ®Google Scholar
• Miller TW, Shin I, Kagawa N, et al. (2008). Aromatase is phosphorylated in situ at serine-118. J Steroid Biochem Mol Biol 112:95–101
   PubMed Web of Science ®Google Scholar
• Mizuno D, Takahashi Y, Hiroi T, et al. (2003). A novel transcriptional element which regulates expression of the CYP2D4 gene by Oct-1 and YY-1 binding. Biochim Biophys Acta 1627:121–128
   PubMed Web of Science ®Google Scholar
• Mizutani T, Shinoda M, Tanaka Y, et al. (2005). Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 37:235–252
   PubMed Web of Science ®Google Scholar
• Modugno F, Knoll C, Kanbour-Shakir A, Romkes M. (2003). A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 82:191–197
   PubMed Web of Science ®Google Scholar
• Mohri T, Nakajima M, Fukami T, et al. (2009). Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79:1045–1052
   PubMed Web of Science ®Google Scholar
• Monostory K, Dvorak Z. (2011). Steroid regulation of drug-metabolizing cytochromes P450. Curr Drug Metab 12:154–172
   PubMed Web of Science ®Google Scholar
• More VR, Cheng Q, Donepudi AC, et al. (2013). Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos 41:1148–1155
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205–216
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. (2013). Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574–582 e571
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Jackson PK. (2011). The tubby family proteins. Genome Biol 12:225
   PubMed Web of Science ®Google Scholar
• Mullin S, Schapira A. (2015). The genetics of Parkinson's disease. Br Med Bull 114:39–52
   PubMed Web of Science ®Google Scholar
• Nakai K, Tanaka H, Hanada K, et al. (2008). Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 36:1786–1793
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yokoi T. (2011). MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther 131:330–337
   PubMed Web of Science ®Google Scholar
• Nalls MA, Pankratz N, Lill CM, et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46:989–993
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. (2002). Clinical importance of the cytochromes P450. Lancet 360:1155–1162
   PubMed Web of Science ®Google Scholar
• Nebert DW, Wikvall K, Miller WL. (2013). Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368:20120431
   PubMed Web of Science ®Google Scholar
• Negro F. (2014). Hepatitis C in 2013: HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 11:77–78
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SM, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18
   PubMedGoogle Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385:956–965
   PubMed Web of Science ®Google Scholar
• Neve EP, Ingelman-Sundberg M. (2008). Intracellular transport and localization of microsomal cytochrome P450. Anal Bioanal Chem 392:1075–1084
   PubMed Web of Science ®Google Scholar
• Neve EP, Ingelman-Sundberg M. (2010). Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum. Curr Opin Drug Discov Dev 13:78–85
   PubMed Web of Science ®Google Scholar
• Newsome AW, Nelson D, Corran A, et al. (2013). The cytochrome P450 complement (CYPome) of Mycosphaerella graminicola. Biotechnol Appl Biochem 60:52–64
   PubMed Web of Science ®Google Scholar
• Ning M, Koh KH, Pan X, Jeong H. (2015). Hepatocyte nuclear factor (HNF) 4α transactivation of cytochrome P450 (Cyp) 2d40 promoter is enhanced during pregnancy in mice. Biochem Pharmacol 94:46–52
   PubMed Web of Science ®Google Scholar
• Nussbaum RL, Ellis CE. (2003). Alzheimer's disease and Parkinson's disease. N Engl J Med 348:1356–1364
   PubMed Web of Science ®Google Scholar
• Obach RS, Pablo J, Mash DC. (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos 26:764–768
   PubMed Web of Science ®Google Scholar
• Oesch-Bartlomowicz B, Oesch F. (2003). Cytochrome-P450 phosphorylation as a functional switch. Arch Biochem Biophys 409:228–234
   PubMed Web of Science ®Google Scholar
• Oesch-Bartlomowicz B, Richter B, Becker R, et al. (2001). cAMP-dependent phosphorylation of CYP2B1 as a functional switch for cyclophosphamide activation and its hormonal control in vitro and in vivo. Int J Cancer 94:733–742
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Schaefer O, Kawakami H, et al. (2012). Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab Dispos 40:83–92
   PubMed Web of Science ®Google Scholar
• Okazaki Y, Furuno M, Kasukawa T, et al. (2002). Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 420:563–573
   PubMed Web of Science ®Google Scholar
• Olinga P, Elferink MG, Draaisma AL, et al. (2008). Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 33:380–389
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378
   PubMed Web of Science ®Google Scholar
• Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. (1997). A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034–1040
   PubMed Web of Science ®Google Scholar
• Ourlin JC, Lasserre F, Pineau T, et al. (2003). The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 17:1693–1703
   PubMed Web of Science ®Google Scholar
• Pabona JM, Simmen FA, Nikiforov MA, et al. (2012). Kruppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: Implications for the pathogenesis of endometriosis. J Clin Endocrinol Metab 97:E376–E392
   PubMed Web of Science ®Google Scholar
• Pai HV, Kommaddi RP, Chinta SJ, et al. (2004). A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J Biol Chem 279:27383–27389
   PubMed Web of Science ®Google Scholar
• Pan X, Jeong H. (2015). Estrogen-induced cholestasis leads to repressed CYP2D6 expression in CYP2D6-humanized mice. Mol Pharmacol 88:106–112
   PubMed Web of Science ®Google Scholar
• Pan X, Lee YK, Jeong H. (2015). Farnesoid X receptor agonist represses cytochrome P450 2D6 expression by upregulating small heterodimer partner. Drug Metab Dispos 43:1002–1007
   PubMed Web of Science ®Google Scholar
• Pandey AV, Fluck CE. (2013). NADPH P450 oxidoreductase: Structure, function, and pathology of diseases. Pharmacol Ther 138:229–254
   PubMed Web of Science ®Google Scholar
• Park HJ, Choi YJ, Kim JW, et al. (2015). Differences in the epigenetic regulation of cytochrome P450 genes between human embryonic stem cell-derived hepatocytes and primary hepatocytes. PLoS One 10:e0132992
   PubMed Web of Science ®Google Scholar
• Patel SA, Bhambra U, Charalambous MP, et al. (2014). Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. Br J Cancer 111:2287–2296
   PubMed Web of Science ®Google Scholar
• Patin E, Kutalik Z, Guergnon J, et al. (2012). Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143:1244–1252 e1–12
   PubMed Web of Science ®Google Scholar
• Pavek P, Dvorak Z. (2008). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129–143
   PubMed Web of Science ®Google Scholar
• Pavek P, Smutny T. (2014). Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier. Drug Metab Rev 46:19–32
   PubMed Web of Science ®Google Scholar
• Persad AS, Stedeford T, Tanaka S, et al. (2003). Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis. Neuroepidemiology 22:357–361
   PubMed Web of Science ®Google Scholar
• Petrescu AD, Hertz R, Bar-Tana J, et al. (2002a). Ligand specificity and conformational dependence of the hepatic nuclear factor-4α (HNF-4α). J Biol Chem 277:23988–23999
   PubMed Web of Science ®Google Scholar
• Pichette V, Leblond FA. (2003). Drug metabolism in chronic renal failure. Curr Drug Metab 4:91–103
   PubMed Web of Science ®Google Scholar
• Polednak AP. (2012). U.S. mortality from liver cirrhosis and alcoholic liver disease in 1999-2004: Regional and state variation in relation to per capita alcohol consumption. Subst Use Misuse 47:202–213
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. (2010). Alzheimer's disease. N Engl J Med 362:329–344
   PubMed Web of Science ®Google Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849–857
   PubMed Web of Science ®Google Scholar
• Raimundo S, Fischer J, Eichelbaum M, et al. (2000). Elucidation of the genetic basis of the common ‘intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577–581
   PubMedGoogle Scholar
• Raimundo S, Toscano C, Klein K, et al. (2004). A novel intronic mutation, 2988G > A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128–138
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Liu Y, Philips S, et al. (2013). Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos 41:1763–1768
   PubMed Web of Science ®Google Scholar
• Redlich G, Zanger UM, Riedmaier S, et al. (2008). Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res 7:4678–4688
   PubMed Web of Science ®Google Scholar
• Reitz C, Mayeux R. (2014). Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88:640–651
   PubMed Web of Science ®Google Scholar
• Renton KW. (2001). Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147–163
   PubMed Web of Science ®Google Scholar
• Renton KW. (2005). Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629–640
   PubMedGoogle Scholar
• Renwick AB, Watts PS, Edwards RJ, et al. (2000). Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28:1202–1209
   PubMed Web of Science ®Google Scholar
• Rhinn H, Fujita R, Qiang L, et al. (2013). Integrative genomics identifies APOE ɛ4 effectors in Alzheimer's disease. Nature 500:45–50
   PubMed Web of Science ®Google Scholar
• Rieger JK, Reutter S, Hofmann U, et al. (2015). Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos 43:884–888
   PubMed Web of Science ®Google Scholar
• Rizzo G, Renga B, Mencarelli A, et al. (2005). Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 5:289–303
   PubMedGoogle Scholar
• Roby CA, Anderson GD, Kantor E, et al. (2000). St John's Wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 67:451–457
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, et al. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–7622
   PubMed Web of Science ®Google Scholar
• Runge D, Kohler C, Kostrubsky VE, et al. (2000). Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273:333–341
   PubMed Web of Science ®Google Scholar
• Sabbagh N, Brice A, Marez D, et al. (1999). CYP2D6 polymorphism and Parkinson's disease susceptibility. Mov Disord 14:230–236
   PubMed Web of Science ®Google Scholar
• Sahi J, Grepper S, Smith C. (2010). Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. Curr Drug Discov Technol 7:188–198
   PubMedGoogle Scholar
• Sakuyama K, Sasaki T, Ujiie S, et al. (2008). Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 36:2460–2467
   PubMed Web of Science ®Google Scholar
• Scandlyn MJ, Stuart EC, Rosengren RJ. (2008). Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413–424
   PubMed Web of Science ®Google Scholar
• Scordo MG, Dahl ML, Spina E, et al. (2006). No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. Pharmacol Res 53:162–165
   PubMed Web of Science ®Google Scholar
• Segura M, Farre M, Pichini S, et al. (2005). Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: Use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649–660
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. (2013). SnapShot: Pathobiology of Alzheimer's disease. Cell 154:468–468 e461
   PubMed Web of Science ®Google Scholar
• Seol W, Choi HS, Moore DD. (1996). An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272:1336–1339
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. (2015). Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: Hypothesis with implications for personalized medicine. Drug Metab Dispos 43:400–410
   PubMed Web of Science ®Google Scholar
• Shedlofsky SI, Israel BC, McClain CJ, et al. (1994). Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94:2209–2214
   PubMed Web of Science ®Google Scholar
• Shimozawa O, Sakaguchi M, Ogawa H, et al. (1993). Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen. J Biol Chem 268:21399–21402
   PubMed Web of Science ®Google Scholar
• Shiotani A, Murao T, Fujita Y, et al. (2013). Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One 8:e84244
   PubMed Web of Science ®Google Scholar
• Siegle I, Fritz P, Eckhardt K, et al. (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237–245
   PubMedGoogle Scholar
• Siest G, Jeannesson E, Marteau JB, et al. (2008). Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 36:182–189
   PubMed Web of Science ®Google Scholar
• Simmen RC, Heard ME, Simmen AM, et al. (2015). The Kruppel-like factors in female reproductive system pathologies. J Mol Endocrinol 54:R89–R101
   PubMedGoogle Scholar
• Simon-Sanchez J, Gasser T. (2015). Parkinson disease GWAS: The question of lumping or splitting is back again. Neurology 84:966–967
   PubMed Web of Science ®Google Scholar
• Simpson ER, Clyne C, Rubin G, et al. (2002). Aromatase − A brief overview. Annu Rev Physiol 64:93–127
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Poulsen L, Brosen K, et al. (1993). Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 53:335–339
   PubMed Web of Science ®Google Scholar
• Singh NK, Banerjee BD, Bala K, et al. (2014). Polymorphism in cytochrome P450 2D6, glutathione S-transferases π1 Genes, and organochlorine pesticides in Alzheimer disease: A case-control study in North Indian population. J Geriatr Psychiatry Neurol 27:119–127
   PubMed Web of Science ®Google Scholar
• Sinz M, Wallace G, Sahi J. (2008). Current industrial practices in assessing CYP450 enzyme induction: Preclinical and clinical. AAPS J 10:391–400
   PubMed Web of Science ®Google Scholar
• Smith RP, Eckalbar WL, Morrissey KM, et al. (2014). Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet 10:e1004648
   PubMedGoogle Scholar
• Smutny T, Mani S, Pavek P. (2013). Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metab 14:1059–1069
   PubMed Web of Science ®Google Scholar
• Snider NT, Sikora MJ, Sridar C, et al. (2008). The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538–545
   PubMed Web of Science ®Google Scholar
• Sokol CL, Luster AD. (2015). The chemokine system in innate immunity. Cold Spring Harb Perspect Biol 7:pii:a016303
   Google Scholar
• Sopko R, Andrews BJ. (2008). Linking the kinome and phosphorylome − A comprehensive review of approaches to find kinase targets. Mol Biosyst 4:920–933
   PubMed Web of Science ®Google Scholar
• Sousa M, Pozniak A, Boffito M. (2008). Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 62:872–878
   PubMed Web of Science ®Google Scholar
• Spaggiari D, Geiser L, Daali Y, Rudaz S. (2014). A cocktail approach for assessing the in vitro activity of human cytochrome P450s: An overview of current methodologies. J Pharm Biomed Anal 101:221–237
   PubMed Web of Science ®Google Scholar
• Stage TB, Pedersen RS, Damkier P, et al. (2015). Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. Br J Clin Pharmacol 79:298–306
   PubMed Web of Science ®Google Scholar
• Stefanovic M, Topic E, Ivanisevic AM, et al. (2000). Genotyping of CYP2D6 in Parkinson's disease. Clin Chem Lab Med 38:929–934
   PubMed Web of Science ®Google Scholar
• Steiner E, Iselius L, Alvan G, et al. (1985). A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394–401
   PubMed Web of Science ®Google Scholar
• Stevens JC, Marsh SA, Zaya MJ, et al. (2008). Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36:1587–1593
   PubMed Web of Science ®Google Scholar
• Stout SM, Nielsen J, Bleske BE, et al. (2010). The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther 15:373–379
   PubMed Web of Science ®Google Scholar
• Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37:1025–1034
   PubMed Web of Science ®Google Scholar
• Strushkevich N, Usanov SA, Plotnikov AN, et al. (2008). Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 380:95–106
   PubMed Web of Science ®Google Scholar
• Sun H, Frassetto L, Benet LZ. (2006). Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1–11
   PubMed Web of Science ®Google Scholar
• Sun Y, Li H. (2013). Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 4:103–116
   PubMed Web of Science ®Google Scholar
• Syme MR, Paxton JW, Keelan JA. (2004). Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487–514
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. (1999). CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55:177–184
   PubMed Web of Science ®Google Scholar
• Tan M, Gu Q, He H, et al. (2008). SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1α ubiquitination and degradation. Oncogene 27:1404–1411
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. (2009). Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109
   PubMed Web of Science ®Google Scholar
• Tang SW, Helmeste D. (2008). Paroxetine. Expert Opin Pharmacother 9:787–794
   PubMed Web of Science ®Google Scholar
• Temesvari M, Kobori L, Paulik J, et al. (2012). Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 341:294–305
   PubMed Web of Science ®Google Scholar
• Teodoro JS, Rolo AP, Palmeira CM. (2011). Hepatic FXR: Key regulator of whole-body energy metabolism. Trends Endocrinol Metab 22:458–466
   PubMed Web of Science ®Google Scholar
• ter Beek J, Guskov A, Slotboom DJ. (2014). Structural diversity of ABC transporters. J Gen Physiol 143:419–435
   PubMed Web of Science ®Google Scholar
• Tian R, Koyabu N, Morimoto S, et al. (2005). Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 33:547–554
   PubMed Web of Science ®Google Scholar
• Tirona RG, Lee W, Leake BF, et al. (2003). The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220–224
   PubMed Web of Science ®Google Scholar
• Topletz AR, Le HN, Lee N, et al. (2013). Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy. Drug Metab Dispos 41:312–319
   PubMed Web of Science ®Google Scholar
• Toscano C, Klein K, Blievernicht J, et al. (2006). Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G > A: Evidence for modulation of splicing events. Pharmacogenet Genomics 16:755–766
   PubMed Web of Science ®Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, et al. (2005). Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192:633–639
   PubMed Web of Science ®Google Scholar
• Trautwein C, Ramadori G, Gerken G, et al. (1992). Regulation of cytochrome P450 2D by acute phase mediators in C3H/HeJ mice. Biochem Biophys Res Commun 182:617–623
   PubMed Web of Science ®Google Scholar
• Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. (1991). Expression of CYP2D6 in developing human liver. Eur J Biochem 202:583–588
   PubMedGoogle Scholar
• Trinh J, Farrer M. (2013). Advances in the genetics of Parkinson disease. Nat Rev Neurol 9:445–454
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Takagi S, et al. (2006). MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66:9090–9098
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Sugimoto S, Nagatomo M, et al. (2014). Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. Ther Apher Dial 18:174–180
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Li Y, Li NY, et al. (1999). Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan. Drug Metab Dispos 27:924–930
   PubMed Web of Science ®Google Scholar
• Ulbricht C, Chao W, Costa D, et al. (2008). Clinical evidence of herb-drug interactions: A systematic review by the natural standard research collaboration. Curr Drug Metab 9:1063–1120
   PubMed Web of Science ®Google Scholar
• Uno Y, Uehara S, Kohara S, et al. (2010). Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab Dispos 38:1486–1492
   PubMed Web of Science ®Google Scholar
• Urabe Y, Ochi H, Kato N, et al. (2013). A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol 58:875–882
   PubMed Web of Science ®Google Scholar
• van der Meer JH, van der Poll T, van‘t Veer C. (2014). TAM receptors, Gas6, and protein S: Roles in inflammation and hemostasis. Blood 123:2460–2469
   PubMed Web of Science ®Google Scholar
• Varner TR, Bookstaver PB, Rudisill CN, Albrecht H. (2011). Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia. Ann Pharmacother 45:967–976
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. (2005). In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845–852
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Pichette V. (2004). Cytochrome P450 and liver diseases. Curr Drug Metab 5:273–282
   PubMed Web of Science ®Google Scholar
• Vincent-Viry M, Fournier B, Galteau MM. (2000). Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos 28:617–619
   PubMed Web of Science ®Google Scholar
• Vincent-Viry M, Muller J, Fournier B, et al. (1991). Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Clin Chem 37:327–332
   PubMed Web of Science ®Google Scholar
• von Otter M, Bergstrom P, Quattrone A, et al. (2014). Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease − A multicenter study. BMC Med Genet 15:131
   PubMed Web of Science ®Google Scholar
• Wang D, Jiang Z, Shen Z, et al. (2011). Functional evaluation of genetic and environmental regulators of p450 mRNA levels. PLoS One 6:e24900
   PubMed Web of Science ®Google Scholar
• Wang H, Li R, Shen Y. (2013). β-Secretase: Its biology as a therapeutic target in diseases. Trends Pharmacol Sci 34:215–225
   PubMed Web of Science ®Google Scholar
• Wang X, Li J, Dong G, Yue J. (2014). The endogenous substrates of brain CYP2D. Eur J Pharmacol 724:211–218
   PubMed Web of Science ®Google Scholar
• Wang Y, Liao M, Hoe N, et al. (2009). A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem 284:5671–5684
   PubMed Web of Science ®Google Scholar
• Wang Z, Gorski JC, Hamman MA, et al. (2001). The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317–326
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Holloway MG. (2009). Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215–228
   PubMed Web of Science ®Google Scholar
• Wenk M, Todesco L, Krahenbuhl S. (2004). Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 57:495–499
   PubMed Web of Science ®Google Scholar
• Wenzel-Seifert K, Wittmann M, Haen E. (2011). QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 108:687–693
   PubMed Web of Science ®Google Scholar
• Werck-Reichhart D, Feyereisen R. (2000). Cytochromes P450: A success story. Genome Biol 1:REVIEWS3003
   PubMedGoogle Scholar
• Weuve J, Hebert LE, Scherr PA, Evans DA. (2014). Deaths in the United States among persons with Alzheimer's disease (2010-2050). Alzheimers Dement 10:e40–e46
   PubMedGoogle Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. (2013). Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Ward A, et al. (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464–468
   PubMed Web of Science ®Google Scholar
• Williamson B, Dooley KE, Zhang Y, et al. (2013). Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 57:6366–6369
   PubMed Web of Science ®Google Scholar
• Wissemann WT, Hill-Burns EM, Zabetian CP, et al. (2013). Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet 93:984–993
   PubMed Web of Science ®Google Scholar
• Woo SI, Kim JW, Seo HG, et al. (2001). CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 55:373–377
   PubMed Web of Science ®Google Scholar
• Wray GA, Hahn MW, Abouheif E, et al. (2003). The evolution of transcriptional regulation in eukaryotes. Mol Biol Evol 20:1377–1419
   PubMed Web of Science ®Google Scholar
• Wu H, Liu Z, Ling G, et al. (2013). Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model. Toxicol Sci 135:476–485
   PubMed Web of Science ®Google Scholar
• Xiao WJ, Ma T, Ge C, et al. (2015). Modulation of the pentose phosphate pathway alters phase I metabolism of testosterone and dextromethorphan in HepG2 cells. Acta Pharmacol Sin 36:259–267
   PubMed Web of Science ®Google Scholar
• Yan R, Vassar R. (2014). Targeting the β-secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 13:319–329
   PubMed Web of Science ®Google Scholar
• Yang AK, He SM, Liu L, et al. (2010a). Herbal interactions with anticancer drugs: Mechanistic and clinical considerations. Curr Med Chem 17:1635–1678
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, et al. (2008). Cytochrome p450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384–394
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang B, Molony C, et al. (2010b). Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20:1020–1036
   PubMed Web of Science ®Google Scholar
• Yang XX, Hu ZP, Duan W, et al. (2006). Drug-herb interactions: Eliminating toxicity with hard drug design. Curr Pharm Des 12:4649–4664
   PubMed Web of Science ®Google Scholar
• Yasukochi Y, Satta Y. (2011). Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst 86:109–116
   PubMed Web of Science ®Google Scholar
• Yasukochi Y, Satta Y. (2015). Molecular evolution of the CYP2D subfamily in primates: Purifying selection on substrate recognition sites without the frequent or long-tract gene conversion. Genome Biol Evol 7:1053–1067
   PubMed Web of Science ®Google Scholar
• Yeung CK, Shen DD, Thummel KE, Himmelfarb J. (2014). Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85:522–528
   PubMed Web of Science ®Google Scholar
• Yu AM. (2008). Indolealkylamines: Biotransformations and potential drug-drug interactions. AAPS J 10:242–253
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Byrd LG, et al. (2003a). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173–181
   PubMedGoogle Scholar
• Yu AM, Idle JR, Herraiz T, et al. (2003b). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307–319
   PubMedGoogle Scholar
• Yu AM, Idle JR, Krausz KW, et al. (2003c). Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic β-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305:315–322
   PubMed Web of Science ®Google Scholar
• Yu JT, Tan L, Hardy J. (2014). Apolipoprotein E in Alzheimer's disease: An update. Annu Rev Neurosci 37:79–100
   PubMed Web of Science ®Google Scholar
• Yuan X, Ta TC, Lin M, et al. (2009). Identification of an endogenous ligand bound to a native orphan nuclear receptor. PLoS One 4:e5609
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D, Klement S, et al. (2012). Effect of Ginkgo biloba special extract EGb 761(R) on human cytochrome P450 activity: A cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68:553–560
   PubMed Web of Science ®Google Scholar
• Zanger UM, Hauri HP, Loeper J, et al. (1988). Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256–8260
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K, Thomas M, et al. (2014). Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. Clin Pharmacol Ther 95:258–261
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141
   PubMed Web of Science ®Google Scholar
• Zhang LH, Rodriguez H, Ohno S, Miller WL. (1995). Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 92:10619–10623
   PubMed Web of Science ®Google Scholar
• Zhang W, Shields JM, Sogawa K, et al. (1998). The gut-enriched Kruppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion. J Biol Chem 273:17917–17925
   PubMed Web of Science ®Google Scholar
• Zhang WY, Tu YB, Haining RL, Yu AM. (2009). Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. Drug Metab Dispos 37:1–4
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhang D, Michel FJ, et al. (2003). Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells. J Biol Chem 278:21474–21482
   PubMed Web of Science ®Google Scholar
• Zhao LN, Lu L, Chew LY, Mu Y. (2014). Alzheimer's disease – A panorama glimpse. Int J Mol Sci 15:12631–12650
   PubMed Web of Science ®Google Scholar
• Zhao Y, Jensen ON. (2009). Modification-specific proteomics: Strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 9:4632–4641
   PubMed Web of Science ®Google Scholar
• Zhong XB, Leeder JS. (2013). Epigenetic regulation of ADME-related genes: Focus on drug metabolism and transport. Drug Metab Dispos 41:1721–1724
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Duan W, et al. (2005). Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 37:41–213
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, et al. (2003). Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35–98
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689–723
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Lai XS. (2009). Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661–2805
   PubMed Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Li CG, et al. (2007). Identification of drugs that interact with herbs in drug development. Drug Discov Today 12:664–673
   PubMed Web of Science ®Google Scholar
• Zhou ZW, Zhou SF. (2009). Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5:579–605
   PubMed Web of Science ®Google Scholar
• Zhu BT. (2010). On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: Some theoretical considerations. Expert Opin Drug Metab Toxicol 6:483–494
   PubMed Web of Science ®Google Scholar